were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 26, 2003.

William K. Hubbard,

Associate Commissioner for Policy and Planning.

[FR Doc. 03–5074 Filed 3–4–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Dietary Supplement Subcommittee of the Food Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Dietary Supplement Subcommittee of the Food Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on March 25, 2003, from 8 a.m. to 5 p.m.

Location: Holiday Inn (Ballrooms A and B), 10000 Baltimore Ave., College Park, MD, 301–345–6700.

Contact Person: Constance J. Hardy, Center for Food Safety and Applied Nutrition (HFS–811), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740, 301–436–1433, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 10564. Please call the Information Line for up-to-date information on this meeting.

Agenda: To be a dietary supplement as defined in section 201(ff) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321(ff)), a product must contain at least one ''dietary ingredient.'' Section 201(ff)(1) of the act lists those substances that are considered ''dietary ingredients.'' Among other things, the term ''dietary ingredient'' includes a metabolite of any other dietary ingredient defined in section 201(ff)(1) of the act. The statute is ambiguous, however, as to what substances are, or are not, metabolites of other substances. The practical result of this ambiguity is that it is often difficult to determine whether a particular substance meets the dietary ingredient definition and, therefore, whether products containing the substance can be marketed as dietary supplements. The purpose of this meeting is to explore whether there are recognized scientific principles that would facilitate reaching a conclusion as to whether a particular substance is a ''metabolite'' of another substance that is a ''dietary ingredient'' defined in the act and, therefore, is itself a dietary ingredient within the scope of section 201(ff)(1) of the act. The background material for this meeting will be posted on the Internet when available or 1-working day before the meeting at http://www.cfsan.fda.gov/~lrd/vidtel.html.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 17, 2003. Oral presentations from the public will be scheduled on March 25, 2003, between approximately 11 a.m. and 3 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 20, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Constance J. Hardy at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 27, 2003.

Linda Arey Skladany,

Associate Commissioner for External Relations.

[FR Doc. 03–5073 Filed 3–4–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Vaccines and Related Biological Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on March 18, 2003, from 10:30 a.m. to 12:45 p.m.

Location: Food and Drug Administration, 5515 Security Lane, conference room A on the 11th floor, suite 1113, Rockville, MD. This meeting will be held by a telephone conference call. The public is welcome to attend the open portion of the meeting at the location in the first sentence of this paragraph. A speaker phone will be provided at the specified location.

Contact Person: Jody G. Sachs or Denise H. Royster, Food and Drug Administration, Center for Biologics Evaluation and Research (HFM–71), 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12391. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will review and discuss the selection of strains to be included in the influenza virus vaccine for the 2003–2004 season.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 12, 2003. Oral presentations from the public will be scheduled between approximately 11:30 a.m. to 12:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 12, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and

an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Jody G. Sachs or Denise H. Royster at least 7 days in advance of the meeting.

FDA regrets that it was unable to publish this notice 15 days prior to the March 18, 2003, Vaccines and Related Biological Products Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Vaccines and Related Biological Products Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 26, 2003.

William K. Hubbard,

Associate Commissioner for Policy and Planning.

[FR Doc. 03–5075 Filed 3–4–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4491–N–10]

Notice of Intent To Prepare a Draft Environmental Impact Statement for the Salishan Revitalization Project, City of Tacoma, WA

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice of intent.

SUMMARY: HUD gives notice to the public, agencies, and Indian tribes that the City of Tacoma, WA acting under its authority as the Responsible Entity for compliance with the National Environmental Policy Act (NEPA) in accordance with 24 CFR 58.4, and jointly the City of Tacoma and Tacoma Housing Authority (THA) acting under their authority as lead agencies in accordance with the State Environmental Policy Act (SEPA) (Revised Code of Washington (RCW) 43.21) intends to prepare an Environmental Impact Statement (EIS) for the redevelopment of the Salishan housing project. This notice is given in accordance with the Council on Environmental Quality regulations [40 CFR parts 1500–1508].

Lead Agencies: The EIS will be prepared as a joint NEPA and Washington State SEPA document intended to satisfy the requirements of both federal and state environmental statutes. In accordance with specific statutory authority and HUD's regulations under 24 CFR part 58 (Environmental Review Procedures for Entities Assuming HUD Environmental Responsibilities), HUD has authorized the City of Tacoma to assume authority as the NEPA Responsible Entity. The City of Tacoma is also the SEPA lead agency and has agreed to share lead agency status with THA with the City as nominal lead as allowed under Washington Administrative Code 197–11–944. Federal agencies with jurisdiction by law, special expertise, or other special interest should report their interests and indicate their willingness to participate in the EIS process as a ''Cooperating Agency.''

ADDRESSES: Notice of intent to prepare an EIS is hereby given and all interested federal, state, and local agencies, Indian tribes, groups, and the public are invited to comment on the scope of the EIS. Comments relating to the scope of the EIS are requested and will be accepted by the contact person listed below for a period of 30 days following issuance of this notice. Parties interested in receiving future notices to comment on the published Draft EIS should also notify the contact person within the 30-day time period.

FOR FURTHER INFORMATION CONTACT: Karie Hayashi, Land Use Administration Planner, City of Tacoma, 747 Market Street, Tacoma, Washington, 98404; Phone (253) 591–5387, Fax: (253) 591–5433; e-mail: *khayashi@cityoftacoma.org.*

SUPPLEMENTARY INFORMATION:

A. Background

The Salishan Public Housing Development (Salishan) was originally constructed in 1942 as war time temporary housing on 147.7 acres on the east side of Tacoma. Located in what is known as the East Side neighborhood, Salishan is bordered on the west by Portland Avenue and on the east by Swan Creek. In 2000, THA submitted a successful HOPE VI grant application for the redevelopment of Salishan. The amount of the HOPE VI grant awarded in connection with the Salishan revitalization project was $35 million. Under the proposed Revitalization Plan, all of the units will be demolished and Salishan will be redeveloped into a community of approximately 1,200 units. The project will require temporary and permanent relocation of all existing residents. The new unit mix will incorporate low-income, affordable, and market rate housing with single- and multi-family dwellings, and senior and special needs housing. The redevelopment project will also include a mixture of commercial uses and improvements to community facilities such as expanding the existing health clinic, day care, family investment center, and gymnasium. There are currently 837 housing units, in which approximately 810 families reside.

Alternatives to be considered in the EIS include a no action alternative and a range of development alternatives from 1,100 units to 1,400 units. An additional option that will be considered as part of the two development alternatives will be a potential land swap with Metro Parks. Metro Parks is proposing to develop a portion of their property and the land they get from THA for active and passive recreation uses. THA will develop the land from Metro Parks for housing or other community facilities.

B. Need for the EIS

This proposal may constitute an action with potentially significant impact on the human environment and significant adverse impacts on the environment. Therefore the lead agencies have elected to prepare an EIS pursuant to 24 CFR 58.37 and RCW 43.21.030(2)(c). Respondents may comment on EIS alternatives, probable significant adverse impacts, mitigation measures, and licenses or other approvals that may be required. Responses to this notice will be used to: (1) Determine significant environmental issues, (2) assist in developing the range of alternatives to be considered, and (3) identify interested parties who would like to participate in the EIS process.

C. Scoping

A public scoping meeting is scheduled to occur on March 19, 2003 from 4 p.m. to 8 p.m. (childcare and language translation services will be available at the meeting). The EIS scoping meeting will provide an opportunity for the public to learn more about the project and provide input on the scope of the EIS. The public scoping meeting will be held at the following location: Tacoma Housing Authority, Salishan Meeting Rooms, 1724 E. 44th Street, Tacoma, Washington 98404.